Market Report, "Mexico Pharmaceuticals & Healthcare Report Q3 2010", published

May 29, 2010 - PRLog -- The value of the total drug market in Mexico will rise from MXN125bn (US$9.26bn) in 2009 to MXN172.66bn (US$16.64bn) by 2014 at a CAGR of 12.4% in US dollar terms. Thereafter the CAGR will slow to 10.13% until 2019, giving a final market value of MXN255.22bn (US$24.31bn). Per-capita spending on medicines will be US$149 in 2014, up from US$86 in 2009, while the proportion of GDP dedicated to drug spending was 1.06% in 2009 and will reach 1.21% by 2014.

The value of the total drug market in Mexico will rise from MXN125bn (US$9.26bn) in 2009 to MXN172.65bn (US$16.6bn) by 2014 at a CAGR of 12.4% in US dollar terms. Thereafter the CAGR will slow to 10.13% until 2019, giving a final market value of MXN255.22bn (US$24.3bn). Per-capita spending on medicines will be US$149 in 2014, up from US$86.1 in 2009, while the proportion of GDP dedicated to drug spending was 1.06% in 2009 and will reach 1.21% by 2014.

Mexican government proposals to increase value-added tax (VAT) on medicines have been met with opposition from the Association of Pharmacies of Mexico (Anafarmex) in February 2010, which claims that this would reduce patients' access to drugs. BMI concurs that taxing medicines is a poor solution to wider economic problems and that pricing out low-income groups will put pressure on the alreadystrained public finances to roll out the Seguro Popular health insurance scheme.

Anafarmex forecast a bleak scenario in which only 60% of patients would be able to afford the higher medicine prices. It also pointed to the 'disorderly' Mexican drug market, where the lack of regulation causes prices to vary between different areas. Enforcing a VAT on medicines would therefore be difficult and unlikely to be uniform. Worse, BMI believes that pharmacies and other dispensers will use any VAT application as an additional means of profiteering - since regulations are weak, the mark-up can be exaggerated, particularly with the country-wide disparities in price.

While the ongoing increase in uptake of Seguro Popular is a positive development, cutting drug prices through promoting generics will increase overall drug sales in Mexico and also boost access to healthcare. In the case of generic drug uptake, industry bodies often point to higher unit volume sales, rather than sales in value terms. However, in the case of Mexico, where there is much by way of unrealised potential in the generic drug sector (though it is being alleviated by improving access to healthcare), we are optimistic that prescription drug sales will be bolstered by the increase in health insurance.

For more information or to purchase this report, go to:
-  http://www.fastmr.com/prod/61107_mexico_pharmaceuticals_h...

Report Table of Contents:

Executive Summary
SWOT Analysis
- Mexico Pharmaceuticals And Healthcare Industry SWOT
- Mexico Political SWOT
- Mexico Economic SWOT
- Mexico Business Environment SWOT
Pharmaceutical Business Environment Ratings
- Table: Americas Pharmaceutical Business Environment Ratings, Q310
- Limits Of Potential Returns
- Risks To Realisation Of Returns
Mexico - Market Summary
Regulatory Regime
- Intellectual Property Environment
- Table: Mexican Marketing Applications In Alleged Violation Of Patent Rights
- Counterfeit Drugs
- Pricing And Reimbursement Issues
- Other Regulatory Developments
Industry Developments
- Epidemiology
- Healthcare Sector
- Health Insurance
- Medical Tourism
- Pharmaceutical Sector
- Generic Drug Sector
- Multinational Activity
- Recent Pharmaceutical Company Activity
- Research And Development Sector
- Retail And Distribution Sector
Industry Forecast Scenario
- Overall Market Forecast
Key Growth Factors - Industry
- Macroeconomic Forecasts
- Table: Mexico - Economic Activity
- Prescription Drug Market Forecast
- OTC Drug Market Forecast
- Generic Drug Market Forecast
- Patented Product Market Forecast
- Medical Device Market Forecast
- Pharmaceutical Trade Forecast
- Other Healthcare Data
- Key Risks To BMI's Forecast Scenario
Company Profiles
- Indigenous Manufacturer Profile
- Liomont
- Strides Latina (Solara)
- Genomma Labs
- Multinational Companies
- Pfizer
- GlaxoSmithKline (GSK)
- Sanofi-Aventis
- Eli Lilly
- Bristol-Myers Squibb (BMS)
- Novartis Farmaceutica
- Bayer
- Boehringer Ingelheim Promeco
- Merck KGaA
- Roche
Country Snapshot: Mexico Demographic Data
- Section 1: Population
- Table: Demographic Indicators, 2005-2030
- Table: Rural/Urban Breakdown, 2005-2030
- Section 2: Education And Healthcare
- Table: Education, 2002-2005
- Table: Vital Statistics, 2005-2030
- Section 3: Labour Market And Spending Power
- Table: Employment Indicators, 2001-2006
- Table: Consumer Expenditure, 2000-2012 (US$)
- Table: Average Annual Wages, 2000-2012
BMI Methodology
- How We Generate Our Pharmaceutical Industry Forecasts
- Pharmaceutical Business Environment Ratings Methodology
- Ratings Overview
- Table: Pharmaceutical Business Environment Indicators
- Weighting
- Table: Weighting Of Components
- Sources
Forecast Tables

About Business Monitor International

Business Monitor International (BMI) offers a comprehensive range of products and services designed to help senior executives, analysts and researchers assess and better manage operating risks, and exploit business opportunities, across 175 markets.  BMI offers three main areas of expertise: Country Risk BMI's country risk and macroeconomic forecast portfolio includes weekly financial market reports, monthly regional Monitors, and in-depth quarterly Business Forecast Reports.  Industry Analysis BMI covers a total of 17 industry verticals through a portfolio of services, including in-depth quarterly Country Forecast Reports.  View more research from Business Monitor International at http://www.fastmr.com/catalog/publishers.aspx?pubid=1010

About Fast Market Research

Fast Market Research is an online aggregator and distributor of market research and business information. We represent the world's top research publishers and analysts and provide quick and easy access to the best competitive intelligence available.

For more information about these or related research reports, please visit our website at http://www.fastmr.com or call us at 1.800.844.8156.